Physician profile
Paul Johnson
NPI 1164682134
$1,817.03
in general payments reported to CMS, 2019-2025
22 companies · $293 in 2025
The $293 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $191 · 2021: $167 · 2022: $206 · 2023: $514 · 2024: $340 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $355.49 | 2019-2025 | |
| Amgen INC. | $260.29 | 2020-2025 | Repatha, Repatha |
| Cardiva Medical, INC. | $253.24 | 2020-2023 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $230.08 | 2019-2025 | Lifevest |
| Shockwave Medical, INC | $125.82 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Edwards Lifesciences Corporation | $84.82 | 2020-2025 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $62.15 | 2019-2024 | Xarelto |
| Abbott Laboratories | $51.02 | 2019-2020 | |
| Cardiovascular Systems INC. | $49.08 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $45.42 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $39.78 | 2019-2020 | |
| Csl Behring | $37.22 | 2022 | |
| Pfizer INC. | $36.89 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.90 | 2021-2022 | |
| Boston Scientific Corporation | $31.12 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $20.89 | 2023 | Ffrct |
| Chiesi USA, INC. | $19.73 | 2024 | Kengreal |
| E.R. Squibb & Sons, L.L.C. | $17.39 | 2023 | Camzyos |
| Astrazeneca Pharmaceuticals Lp | $17.08 | 2024 | Wainua |
| Bridgebio Pharma, INC. | $16.33 | 2025 | Attruby |
| Cvrx, INC. | $14.71 | 2023 | Barostim Neo System |
| Irhythm Technologies, INC. | $14.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.